Clinical Trial Update: A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update summarizes safety and efficacy findings for LentiGlobin BB305 in patients with β-thalassemia major across Phase 1/Phase 2, with completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia Major

Drugs mentioned

• LentiGlobin BB305 Drug Product (BB305)

Snippet

Sponsor: Genetix Biotherapeutics Inc. | Conditions: β-thalassemia Major | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-08